Truist Financial
HRMY icon

Truist Financial’s Harmony Biosciences HRMY Stock Holding History

Truist Financial’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,979
Closed -$271K – 2600
2024
Q2 		$271K Buy
8,979
+13
+0.1% +$391 ﹤0.01% 2338
2024
Q1 		$301K Sell
8,966
-221
-2% -$7.09K ﹤0.01% 2285
2023
Q4 		$297K Buy
+9,187
New +$256K ﹤0.01% 2310
2023
Q3 		– Sell
-6,149
Closed -$216K – 2626
2023
Q2 		$216K Sell
6,149
-1,365
-18% -$47.1K ﹤0.01% 2412
2023
Q1 		$245K Buy
7,514
+16
+0.2% +$729 ﹤0.01% 2325
2022
Q4 		$413K Buy
+7,498
New +$412K ﹤0.01% 2091

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truist Financial's HRMY Position: Q3 2024 in Review

Truist Financial sold out of Harmony Biosciences (HRMY) in Q3 2024, closing a stake of 8,979 shares — an estimated $271K sold.

Truist Financial first reported a position in HRMY in Q4 2022 and held it in 6 quarters. The position peaked at $413K in Q4 2022. 233 funds tracked by Wall St. Rank hold HRMY as of Q3 2024.

  • Truist Financial reported no remaining Harmony Biosciences position as of Q3 2024 after selling out during the quarter.
  • Truist Financial sold 8,979 Harmony Biosciences shares in Q3 2024, an estimated $271K.
  • Truist Financial first reported a position in Harmony Biosciences in Q4 2022 and held it in 6 quarters.
  • Truist Financial's Harmony Biosciences position peaked at $413K in Q4 2022.
  • 233 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2024.

Based on Truist Financial's 13F filing for Q3 2024, filed 13 Nov 2024.